Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children

Conditions:Cancer, Blood Cancer
Therapuetic Areas:Oncology
Age Range:Any - 29
Start Date:July 2015
End Date:December 2019
Contact:Jessica Boklan, MD

Use our guide to learn which trials are right for you!

Phase I Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed and Refractory Solid Tumors and Leukemias

This study evaluates the use of carfilzomib in combination with cyclophosphamide and
etoposide for children with relapsed/refractory solid tumors or leukemia. The medications
cyclophosphamide and etoposide are standard drugs often used together for the treatment of
cancer in children with solid tumors or leukemia.

Carfilzomib is FDA (Food and Drug Administration) approved in the United States for adults
with multiple myeloma (a type of cancer). However, this drug is not approved for the disease
being treated in this study. Since carfilzomib has not yet been used in this setting to treat
this condition, the investigators must first find the best dose to give. The investigators
are looking for the highest dose of carfilzomib that can be given safely. Therefore, not all
children taking part in this study will receive the same dose of the study drug in the first
part of the trial.

The purpose of this study is to find out what effects, good and/or bad, treatment with a new
combination of drugs, cyclophosphamide, etoposide, and carfilzomib has on cancer.

In part 1 of the trial, small groups of children will be enrolled in steps. The first group
will be given a certain dose of carfilzomib. If these children do not have side effects which
are too bad, the next small group of children enrolled will receive a higher dose. This
increase in doses with groups of people will continue until we find the highest dose of the
drug that can be given without causing severe or unmanageable side effects.

Part 2 of this study will enroll additional patients at the highest tolerable dose found in
Part 1 in order to get more information on side effects and make sure the dose is tolerable.

Inclusion Criteria:

1. Patients must have either of the following:

1. Relapsed/refractory leukemia in 2nd or greater relapse or who have failed at
least one re-induction attempt after relapse or for refractory disease. Patients
must meet the WHO classification with ≥ 5% blasts in the bone marrow or must have
definitive extramedullary disease (e.g. chloromas, skin lesions). Patients may
have asymptomatic CNS 1 or CNS 2 disease, but not CNS 3 or symptomatic CNS


2. Relapsed/refractory non-CNS solid tumor that has not responded or has relapsed
and for which no standard treatment is available. Patients may not have primary
CNS tumors or CNS metastases. Lymphoma patients are permitted. Patients do not
need to have measurable disease.

2. Age 6 months - 29.99 years at enrollment

3. Life expectancy ≥ 3 months

4. Lansky or Karnofsky ≥50

5. Prior therapy

1. Patient must have fully recovered from the acute toxic effects of all prior
chemotherapy, immunotherapy, radiotherapy, or surgery prior to study entry.

2. Myelosuppressive therapy- At least 14 days must have elapsed since the
administration of previous therapy. Six weeks must have elapsed from the
administration of nitrosureas or mitomycin C. For patients with ALL on
maintenance therapy, they may be eligible if 7 days have elapsed and they are
recovered from the toxic effects of the chemotherapy. This restriction does not
include intrathecal chemotherapy, which is permitted.

3. Biologic agents- At least 14 days must have elapsed since the completion of
therapy with a biologic agent such as a monoclonal antibody. Seven days must have
elapsed since the last dose of retinoids

4. Radiation therapy - At least 14 days must have elapsed for local XRT. At least 90
days must have elapsed if prior radiation to ≥50% of the pelvis, the spine, or
other substantial bone marrow radiation including TBI.

5. Hematopoietic growth factors- At least 7 days must have elapsed since the last
dose of G-CSF or GM-CSF. At least 14 days must have elapsed since last dose of
pegfilgrastim (Neulasta®).

6. Patient must be ≥ 3 months from hematopoietic stem cell transplant, must not have
active GVHD, and must be off all immunosuppression

7. Organ function:

1. Either a serum creatinine ≤ ULN for age, or calculated or measured GFR ≥ 70
mL/min/1.73 m2

2. Total bilirubin ≤ 1.5 x ULN for age, direct bilirubin ≤ ULN for age

3. AST and ALT ≤ 3 x ULN for age unless elevation can be clearly attributed to liver
leukemia or metastases

4. ECHO shortening fraction ≥ 27%

5. Pulse Oximetry measurement ≥ 95% saturation without supplemental oxygen

8. Bone marrow function:

1. Hgb ≥10 g/dL - can be transfused

2. Plts ≥ 75,000 - cannot be transfused (must be ≥ 7 days from last plt transfusion)

3. ANC ≥ 750 - cannot be transfused (must be ≥ 72 hours from last neutrophil

However, the plt and ANC requirements can be waived if low counts thought to be
secondary to leukemia or tumor bone marrow infiltration

9. Reproductive function:

1. Female patients of childbearing potential must have a negative serum pregnancy
test confirmed within 7 days prior to enrollment

2. Female patients with infants must agree not to breastfeed their infants while on
the study

3. Male and female patients of child-bearing potential must agree to use an
effective method of contraception approved by the investigator during the study
and for a minimum of 3 months after study treatment

10. Written informed consent

Exclusion Criteria:

1. Prior treatment with carfilzomib

2. Known allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib).

3. Down syndrome

4. Fanconi Anemia or other underlying bone marrow failure syndrome

5. Pregnant or lactating females

6. Known history of Hepatitis B or C or HIV

7. Patient with any significant concurrent illness

8. Patient with uncontrolled systemic fungal, bacterial, viral or other infection with
ongoing signs/symptoms despite appropriate treatment

9. Patient with illness, psychiatric disorder or social issue that could compromise
patient safety or compliance with the protocol treatment or procedures, or interfere
with the consent, study participation, follow-up, or interpretation of study results.
We found this trial at
4502 Medical Drive
San Antonio, Texas 78284
(210) 567-7000
Principal Investigator: Anne-Marie Langevin, MD
Phone: 210-567-7460
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
San Antonio, TX
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
Principal Investigator: Steven DuBois, MD
Phone: 617-632-5460
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Boston, MA
Click here to add this to my saved trials
Calgary, Alberta
Principal Investigator: Aru Narendran, MD, PhD
Phone: 403-210-6418
Click here to add this to my saved trials
500 University Dr
Hershey, Pennsylvania 17033
(717) 531-8521
Principal Investigator: Valerie Brown, MD, PhD
Phone: 717-531-6012
Penn State Hershey Children's Hospital Penn State Milton S. Hershey Medical Center, Penn State College...
Hershey, PA
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Anne Franklin, MD
Phone: 713-792-3497
Houston, TX
Click here to add this to my saved trials
1 Children's Way
Little Rock, Arkansas 72202
(501) 364-1100
Principal Investigator: Kathleen Neville, MD, MS
Phone: 501-364-4405
Arkansas Children's Hospital Arkansas Children's Hospital (ACH) is the only pediatric medical center in Arkansas...
Little Rock, AR
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Tanya Trippett, MD
Phone: 212-639-8267
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
New York, NY
Click here to add this to my saved trials
800 Welch Road
Palo Alto, California 94304
Principal Investigator: Norman Lacayo, MD
Phone: 650-723-5533
Palo Alto, CA
Click here to add this to my saved trials
1919 E Thomas Rd
Phoenix, Arizona 85006
(602) 933-1000
Principal Investigator: Jessica Boklan, MD
Phone: 602-933-5004
Phoenix Children's Hospital Phoenix Children's Hospital has provided hope, healing, and the best healthcare for...
Phoenix, AZ
Click here to add this to my saved trials